Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33746596/
1 Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China. 2 Institute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South...
-
Mark Fesler5yrIt will be interesting to see, now that there is an fda approved myeloma car, what the uptake of this therapy will be in the real world as providers weigh Show More
-
Multiple Myeloma Connect5yrKey points • Dutch researchers assessed the optimal sequence of treatment for patients with non-transplant eligible (NTE) multiple myeloma (MM) from patient, physician, and society vantage points. They assessed 30 treatment sequences, Show More
Immune-related expression profiles of bisphosphonates-related osteonecrosis of the jaw in multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33849701/
Objective: To investigate the immune cellular and genomic profiles of bisphosphonates-related osteonecrosis (BRONJ) of the jaw and excavate potential small molecule drugs. Methods and materials: The genomic profile of a...
Employment of Artificial Intelligence Based on Routine Laboratory Results for the Early Diagnosis of Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33854961/
Objective: In order to enhance the detection rate of multiple myeloma and execute an early and more precise disease management, an artificial intelligence assistant diagnosis system is developed.
Cyclopamine sensitizes multiple myeloma cells to circularly permuted TRAIL-induced apoptosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33732371/
Tumor necrosis factor related apoptosis inducing ligand (TRAIL) is a promising anti-myeloma drug prototype. The aim of the present study was to investigate the synergistic effects of cyclopamine and circularly...
-
Mark Fesler5yrInteresting pharmacologic study demonstrating dual agent inhibition of myeloma cells. Further work hopefully will be done to confirm that this is a clinically relevant pathway